Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVex, a biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious diseases, has reported first patient dosing in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2.
Subscribe to our email newsletter
BioVex said that the Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and is expected to involve up to 42 already identified subjects.
Robert Coffin, founder and CTO at BioVex, said: “Developing an effective vaccine against genital herpes has historically proved challenging. ImmunoVEX is a rationally designed live attenuated vaccine specifically constructed to address the limitations of previous vaccines.
“We believe our vaccine is built on sound science, providing a solid basis upon which to anticipate success in the clinic. We look forward to evaluating the Phase 1 data in late 2010 and based on positive outcomes, moving ImmunoVEX into later stage efficacy trials soon thereafter.”